Chairman of the board at Coloplast Lars Rasmussen says he's had bad experiences with giving the public an insight into tax payments across the world, in an interview with Danish business daily Børsen.
On the one hand, it is good that the medtech company has publicized its tax payments for EU member states prior to the upcoming directive that would make this a requirement, the Coloplast's chair says. On the other, the same information on a global scale is a complicated issue that isn't easy to communicate clearly, he says.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Diabetes center CEO: New Eli Lilly drug is worthy opponent for Novo Nordisk's Ozempic
Allan Flyvbjerg, CEO of Steno Diabetes Center in Copenhagen, says Eli Lilly’s tirzepatide has proved itself a fierce challenger to Novo Nordisk’s newest generation of diabetes drugs.
In a world of options, Genmab's CEO chose partnerships
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.
Analyst predicts slow start for Leo Pharma's Adtralza in UK
The take-up of Leo Pharma’s atopic eczema drug Adtralza in the UK will be slow-going, according to analyst bureau Global Data, after the British institute NICE released draft guidance where it was not recommend it as a standard treatment in England and Wales.
US government exercises option to buy Bavarian smallpox vaccines for USD 119m
The first option in an existing contract with the US has been utilized, and Bavarian Nordic can start manufacturing freeze-dried doses of Jynneos for the country in 2023.
Issues at Novo Nordisk lead to shortage of fast-acting diabetes drug
The Danish Medicines Agency has reported that it is currently difficult to find diabetes drug Novorapid in Denmark.
Cell Culture Scientist/Senior Scientist 
Biostatistician 
IT Solution Architect for R&D and Global Quality applications 
Clinical Project Manager 
Director Global Engineering 
Communications Consultant 
Client Talent Acquisition Specialist 
Consultant Manager 
Vice President, Test & Characterisation 
Senior Manager, Clinical Trial Budget 
System Sales Development Consultant - Investment Projects, Merck Millipore 
KLIFO is looking for a Clinical Supply Manager for our Glostrup office 
Key Account Manager, Europe and Asia 
CMO Operations Specialist - screening & selection of CMO/CDMO’s 
Nordic Medical Affairs Manager